Can an Innovator Founder sell the business before ILR?

The route description in Appendix Innovator Founder requires the applicant to have a key role in the day to day management and development of the business. For a same-business application, INNF 9.4 requires the business to be active, trading and sustainable with significant progress against the business plan; INNF 9.5 requires it to be registered at Companies House with the applicant listed as a director or member; and INNF 10.1 requires the applicant's day to day involvement.

The current caseworker guidance makes the boundary explicit. Where there is reason to believe the applicant is not actively involved, further information must be requested, and a financial interest alone is insufficient. Retaining shares, an earn-out or a founder title cannot therefore substitute for substantive work developing and managing the venture.

None of those provisions fixes a minimum percentage holding. Dilution, a partial secondary sale or the appointment of an experienced chief executive may coexist with a qualifying role. The evidence must nevertheless show what the founder actually decides, builds and delivers after completion.

INNF 17.1 requires the settlement endorsement to confirm significant achievements against the previously assessed business plan, Companies House registration and the applicant's director or member status. It must also confirm that the business is active and trading, appears sustainable for at least the following 12 months, and that the applicant has demonstrated an active key role in day to day management and development.

The endorsement must then confirm at least 2 specified achievements. Those criteria concern investment actively spent, comparative customer growth, research and development with a UK intellectual property application, stated revenue or export revenue thresholds, or qualifying settled-worker jobs. A sale price, enterprise valuation or buyer's strategic interest is not listed as a separate criterion.

An acquisition may supply evidence relevant to the venture's progress, but it does not displace the express tests. The founder must have spent at least 3 years in the UK with Innovator Founder permission, meet continuous residence and knowledge of life requirements, and provide an endorsement letter issued no more than 3 months before applying which has not been withdrawn.

The commercial timetable may be driven by exclusivity, regulatory approval, funding or the buyer's reporting cycle. The immigration timetable is different. The settlement qualifying period, contact points, endorsement assessment, letter date and application date must be plotted before the founder makes an irreversible promise to step down or transfer the operating business.

A founder should not assume that filing a settlement application makes a subsequent resignation irrelevant. The endorsement cannot safely be approached as a historical certificate detached from the facts on which it was issued. If the business or role is due to change during the application process, the position should be assessed before implementation and any required disclosure handled accurately.

Where settlement is not yet available, the alternatives may include changing the structure or timing of the deal, retaining a substantive qualifying role, considering whether the continuing business can still be endorsed, extending rather than settling, or reviewing another immigration route. None should be represented as a universal workaround: each depends on the real transaction and the requirements in force at the relevant date.

The immigration review should start with the endorsement history and business plan, then read the heads of terms, sale and purchase agreement, disclosure materials, post completion governance, service agreement and earn-out conditions. The purpose is not to redraft a transaction around labels, but to establish exactly which business and role remain.

Companies House records, board minutes, delegated authority, product and commercial decisions, management accounts, customer and employee records, intellectual property ownership and evidence of the founder's work should tell a consistent story. A director filing does not prove active management if the founder's correspondence and authority show otherwise.

The endorsing body should receive accurate, properly timed information needed to assess the continuing position. Corporate, tax and immigration advisers should align their factual descriptions: an immigration narrative that contradicts the sale documents or tax treatment creates avoidable credibility risk.